Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lenalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 13/20 | 1.00 |
| ▸ | DDB1 known ✓ | Q16531 | 3/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 1.00 |
| ▸ | IKZF1 | Q13422 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 3/20 | 1.00 |
| ▸ | IL1B | P01584 | 3/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenalidomide SCHEMBL32978 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL30876939 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL17999103 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL18825 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192655 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL29414335 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL29377496 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192663 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192650 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL18917500 | 0.99 | CRBN (0.97) | CRBNIKZF3IKZF1DDB1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 255 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025118133-A1 | (S)-LENALIDOMIDE-5-DERIVATIVE, SYNTHESIS METHOD THEREFOR AND USE THEREOF | 浙江普洛家园药业有限公司 | 2025-06-12 | — | — | WO | claimed |
| US-8586020-B2 | Poly(organophosphazene) composition for biomaterials | KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) | 2013-11-19 | — | — | US | claimed |
| EP-1285916-A1 | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing TNF alpha levels | CELGENE CORPORATION (US) | 2003-02-26 | — | — | EP | claimed |
| EP-4699622-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND OTHER MEDICINE | Daiichi Sankyo Company, Limited (JP) | 2026-02-25 | — | — | EP | disclosed |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | NOVARTIS AG (CH) | 2026-01-22 | — | — | US | disclosed |
| US-20250368750-A1 | SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | NOVARTIS AG (CH) | 2025-12-04 | — | — | US | disclosed |
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | BROWN DENNIS M (US) | 2025-10-09 | — | — | US | disclosed |
| US-12344657-B2 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | NOVARTIS AG (CH) | 2025-07-01 | — | — | US | disclosed |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | BROWN DENNIS M (US) | 2025-06-24 | — | — | US | disclosed |
| US-12338287-B2 | Treatment of cancer using a CD33 chimeric antigen receptor | NOVARTIS AG (CH) | 2025-06-24 | — | — | US | disclosed |
| WO-2025118133-A1 | (S)-LENALIDOMIDE-5-DERIVATIVE, SYNTHESIS METHOD THEREFOR AND USE THEREOF | 浙江普洛家园药业有限公司 | 2025-06-12 | — | — | WO | disclosed |
| EP-2350055-A1 | LENALIDOMIDE SOLVATES AND PROCESSES | Dr. Reddy's Laboratories Ltd. (IN) | 2011-08-03 | — | — | EP | disclosed |
| WO-2011069608-A1 | S-LENALIDOMIDE, POLYMORPHIC FORMS THEREOF AND BLEND COMPRISING S- UND R-LENALIDOMIDE | RATIOPHARM GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| WO-2011069608-A1 | S-LENALIDOMIDE, POLYMORPHIC FORMS THEREOF AND BLEND COMPRISING S- UND R-LENALIDOMIDE | RATIOPHARM GMBH (DE) | 2011-06-16 | — | — | WO | disclosed |
| WO-2010056384-A1 | LENALIDOMIDE SOLVATES AND PROCESSES | DR. REDDY'S LABORATORIES LTD. (IN) | 2010-05-20 | — | — | WO | disclosed |
| EP-2177517-A1 | Amino substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimide for reducing TNF alpha levels | CELGENE CORPORATION (US) | 2010-04-21 | — | — | EP | disclosed |
| US-7629360-B2 | reducing the levels of tumor necrosis factors by administering a drug comprising1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)-4-aminoisoindoline | CELGENE CORPORATION (US) | 2009-12-08 | — | — | US | disclosed |
| US-6555554-B2 | 2,6-dioxopiperidin; antiinflammatory agent; reduces tumor necrosis factor alpha levels and/or increases cAMP | CELGENE CORPORATION | 2003-04-29 | — | — | US | disclosed |
| US-6476052-B1 | Isoindolines, method of use, and pharmaceutical compositions | CELGENE CORPORATION | 2002-11-05 | — | — | US | disclosed |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | MULLER GEORGE W (US) | 2002-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250312347-A1 | THERAPEUTIC BENEFIT OF SUBOPTIMALLY ADMINISTERED CHEMICAL COMPOUNDS | UNG, DPYD, TPMT | CRBN 2004/4885DDB1 278/4885IKZF3 2835/4885 |
| US-20250368750-A1 | SHP INHIBITOR COMPOSITIONS AND USES FOR CHIMERIC ANTIGEN RECEPTOR THERAPY | PTPRCAP, PTPRC, CD47 | CRBN 179/4885DDB1 1785/4885IKZF3 140/4885 |
| US-12344657-B2 | CD20 therapies, CD22 therapies, and combination therapies with a CD19 chimeric antigen receptor (CAR)-expressing cell | CD22, CD2, CD99 | CRBN 376/4885DDB1 1760/4885IKZF3 142/4885 |
| US-12336993-B2 | Therapeutic benefit of suboptimally administered chemical compounds | UNG, DPYD, TPMT | CRBN 2004/4885DDB1 278/4885IKZF3 2835/4885 |
| US-20260021178-A1 | BCMA-TARGETING AGENT, AND COMBINATION THERAPY WITH A GAMMA SECRETASE INHIBITOR | GSAP, BACE1, CD79B | CRBN 120/4885DDB1 960/4885IKZF3 1146/4885 |
| US-20020045643-A1 | Isoindolines, method of use, and pharmaceutical compositions | TNF, OPRK1, OPRD1 | CRBN 4469/4885DDB1 3697/4885IKZF3 1543/4885 |
| US-12338287-B2 | Treatment of cancer using a CD33 chimeric antigen receptor | CD2, FCGR3B, CD58 | CRBN 889/4885DDB1 2912/4885IKZF3 74/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.